Trial Profile
A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms IMMUCHEC
- 13 Sep 2022 Results assessing the the efficacy of tremelimumab (two dosing regimens) in combination with CTx+D in treatment-naive patients with CHolangio- and gallbladdEr Carcinoma presented at the 47th European Society for Medical Oncology Congress
- 01 Jun 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.